静脉化疗联合腹腔热灌注化疗治疗进展期胃癌疗效临床观察

Intraperitoneal Hyperthermic Perfusion Chemotherapy Combined with Intravenous Contrast Chemotherapy Alone in Patients with Advanced Gastric Cancer with Intravenous Chemotherapy

目的:比较进展期胃癌术后静脉化疗联合腹腔热灌注化疗与单纯静脉化疗的疗效。方法:纳入患者60例,随机将患者均分为治疗组、对照组,治疗组采用静脉化疗联合腹腔热灌注化疗进行治疗;对照组仅采用单纯静脉化疗进行治疗。每21天为1疗程,共6个疗程。观察两组患者生存率及不良反应。结果:治疗组术后1年、3年、5年生存率分别为92%、72%、55%,对照组术后1年、3年、5年生存率分别为82%、47%、32%,两组比较,术后1年生存率无显著差异(P>0.05);术后3,5年生存率有显著差异(P<0.05)。治疗腹腔局部复发率为16%、远处转移率为25%;对照组腹腔局部复发率为23%,远处转移率为34%,两组局部复发率比较差异有显著性(P<0.05)。结论:进展期胃癌术后采用静脉化疗联合腹腔热灌注治疗能有效提高患者的长期生存率、且操作简单方便、不良反应少。

Objective：Comparison of advanced gastric cancer postoperative intravenous chemotherapy combined with intraperitoneal hyperthermic perfusion chemotherapy and efficacy of intravenous chemotherapy alone.Methods：A total of 60 patients,the patients were randomly divided into treatment group and control group,the treatment group received intravenous chemotherapy combined with intraperitoneal hyperthermic chemotherapy treatment;the control group,only using a simple intravenous chemotherapy treatment.Every 21 days for a course of treatment,a total of six courses.Survival of the two groups were observed and adverse reactions.Results：The treatment group after 1 year,3 year and 5-year survival rates were 92%,72%,55% in the control group after 1-year,3-year and5-year survival rates were 82%,47%,32 %,respectively,after 1-year survival rate was no significant difference（P〉0.05）;after 3,there is a significant difference（P〈0.05） 5-year survival rate.Treatment of abdominal local recurrence rate was 16%,distant metastasis rate was 25%;the control group were local recurrence rate was 23%,34% distant metastasis,local recurrence rate difference between the two groups was significant（P〈0.05）.Conclusions：Postoperative advanced gastric cancer using chemotherapy combined with intraperitoneal hyperthermic therapy can effectively improve the long-term survival of patients,and simple operation,fewer adverse reactions.